Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Mechanisms of Resistance to Antibody-Drug Conjugates
Rita Khoury, Khalil Saleh, Nadine Khalife, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 11, pp. 9674-9674
Open Access | Times Cited: 54

Showing 26-50 of 54 citing articles:

Exploring the therapeutic potential of ADC combination for triple-negative breast cancer
Linlin Lu, Zihe Niu, Zhujun Chao, et al.
Cellular and Molecular Life Sciences (2023) Vol. 80, Iss. 12
Open Access | Times Cited: 9
The Evolution of Antibody‐Drug Conjugates: Toward Accurate DAR and Multi‐specificity
Wenge Dong, Wanqi Wang, Chan Cao
ChemMedChem (2024) Vol. 19, Iss. 17
Closed Access | Times Cited: 3
Systematic review of recent advancements in antibody-drug and bicycle toxin conjugates for the treatment of urothelial cancer
Chaim Domb, Jorge A. García, Pedro Barata, et al.
Therapeutic Advances in Urology (2024) Vol. 16
Open Access | Times Cited: 3
Advances in CAR-T therapy for central nervous system tumors
Delian Zhou, Xiaojian Zhu, Yi Xiao
Biomarker Research (2024) Vol. 12, Iss. 1
Open Access | Times Cited: 3
Antitumor activities against breast cancers by an afucosylated anti‐HER2 monoclonal antibody H2Mab‐77‐mG2a‐f
Tomohiro Tanaka, Hiroyuki Suzuki, Tomokazu Ohishi, et al.
Cancer Science (2023) Vol. 115, Iss. 1, pp. 298-309
Open Access | Times Cited: 7
Antibody-Drug Conjugates: The New Treatment Approaches for Ovarian Cancer
Sho Sato, Tadahiro Shoji, Ami Jo, et al.
Cancers (2024) Vol. 16, Iss. 14, pp. 2545-2545
Open Access | Times Cited: 2
Immunohistochemical Expression of p53 and FGFR3 Predicts Response to Enfortumab Vedotin in Metastatic Urothelial Carcinoma
Yujiro Nagata, Akinori Minato, Hisami Aono, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 19, pp. 10348-10348
Open Access | Times Cited: 2
Current Status and Future Prospects of TROP-2 ADCs in Lung Cancer Treatment
Mingyi Li, Jin Meng, Hao Peng, et al.
Drug Design Development and Therapy (2024) Vol. Volume 18, pp. 5005-5021
Open Access | Times Cited: 2
Antitumor Activities against Breast Cancers by an Afucosylated Anti-HER2 Monoclonal Antibody H<sub>2</sub>Mab-77-mG<sub>2a</sub>-f
Tomohiro Tanaka, Hiroyuki Suzuki, Tomokazu Ohishi, et al.
(2023)
Open Access | Times Cited: 6
The endosomal-lysosomal system in ADC design and cancer therapy
Jeffrey V. Leyton
Expert Opinion on Biological Therapy (2023) Vol. 23, Iss. 11, pp. 1067-1076
Closed Access | Times Cited: 4
Durable Response After Combination Therapy With Enfortumab Vedotin and Radiotherapy in Metastatic Urothelial Carcinoma: A Report of Two Cases
Daiki Ikarashi, Koyo Kikuchi, Kenta Takahashi, et al.
Cureus (2023)
Open Access | Times Cited: 4
Pioneering the Way: The Revolutionary Potential of Antibody–Drug Conjugates in NSCLC
Xiehui Chen, Changchun Zeng
Current Treatment Options in Oncology (2024) Vol. 25, Iss. 4, pp. 556-584
Closed Access | Times Cited: 1
Design, synthesis and bioactivity evaluation of novel monomethyl auristatin F analogues
Lisheng Yang, Xinglin Li, Lei Zhao, et al.
Molecular Diversity (2024)
Closed Access | Times Cited: 1
Scalable Antigen-Antibody Binding Affinity Landscape: A Case Study with ENHERTU
Wei Li
(2024)
Closed Access | Times Cited: 1
Updated clinical evidence and molecular features of antibody-drug conjugates for advanced urothelial carcinoma
Ching‐Yun Wang, Pai‐Chi Teng, Jian‐Hua Hong
Urological Science (2024) Vol. 35, Iss. 3, pp. 103-111
Open Access | Times Cited: 1
Antibody-Drug Conjugates in Breast Cancer: Toward a Molecular Perspective Into Clinical Practice
Roberto Paz-Manrique, Joseph A. Pinto, Guillermo Valencia
JCO Precision Oncology (2024), Iss. 8
Closed Access | Times Cited: 1
Incidence of antibody–drug conjugate-related hepatotoxicity in breast cancer: a systematic review and meta-analysis
Ping Yang, Hengheng Zhang, Jinming Li, et al.
Therapeutic Advances in Drug Safety (2024) Vol. 15
Open Access | Times Cited: 1
Next-generation antibody–drug conjugates revolutionize the precise classification and treatment of HER2-expressing breast cancer
Lei-Jie Dai, Yuwei Li, Ding Ma, et al.
Cancer Biology and Medicine (2023), pp. 1-6
Open Access | Times Cited: 2
TRPML1 as a potential therapeutic target for triple-negative breast cancer: a review
Ying Pan, Qiancheng Zhao, Haitao He, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 2
Revolutionizing Breast Cancer Treatment: Unveiling the Effectiveness and Safety of Trastuzumab Deruxtecan through a Comprehensive Meta-Analysis
Jiqiu Qin, Sheng Sun, Hong Ma, et al.
Research Square (Research Square) (2024)
Open Access
Design, synthesis and bioactivity evaluation of novel monomethyl auristatin F analogues
Lisheng Yang, Xinglin Li, Lei Zhao, et al.
Research Square (Research Square) (2024)
Open Access
Molecular targets for metastasis-directed therapy in malignant tumors
Vitalina Bodenko, M. S. Larkina, A. A. Prach, et al.
Bulletin of Siberian Medicine (2024) Vol. 23, Iss. 2, pp. 101-113
Open Access
[Research Progress of Antibody-conjugated Drugs in Non-small Cell Lung Cancer].
Y. Liu, Sen Wei
PubMed (2024) Vol. 27, Iss. 6, pp. 431-440
Closed Access
History of trastuzumab: a case study in health technology reassessment and natural disinvestment in Veneto Region
Antonella Giorgia Becchetti, Anna M. Martini, Giovanna Scroccaro, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access
Present Scenario and Future Landscape of Payloads for ADCs: Focus on DNA-Interacting Agents
Barbara Valsasina, Paolo Orsini, Chiara Terenghi, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 10, pp. 1338-1338
Open Access

Scroll to top